FINCAD Launches Pioneering Python Toolkit for Valuation and Risk Analytics
FINCAD, the leading provider of enterprise solutions for derivative and fixed income portfolios, today announced innovative enhancements to FINCAD F3, an advanced valuation and risk analytics solution. A comprehensive Python toolkit has been added to F3, enabling traders, quants, portfolio managers and risk managers to rapidly generate custom analytics, applications and reports to drive better investment and risk decisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181011005479/en/
FINCAD F3 Python Trade Script for a TARN (Photo: Business Wire)
Due to its versatility and ease of use, Python has achieved widespread adoption in finance, and has become the multi-purpose tool of choice for quantitative analysts and other financial technologists. However, while it is easy to start projects with Python, deploying them to production can be challenging, and teams often struggle with infrastructure issues such as data management, calculation scaling, version control, admin and security.
The F3 Python toolkit helps clients address this challenge by combining Python’s sophisticated capabilities, FINCAD’s industry-standard analytics library and the enterprise-class technology of F3 Platform, which automatically handles the infrastructure issues. The result is that portfolio managers, traders, and quants can maximize their productivity and focus on creating real business value without the heavy burden of enterprise infrastructure and software concerns. Common use cases cover a wide range, including strategy back-testing, structured product scripting, portfolio optimization, tailored hedging strategies, LDI portfolio construction, cash flow matching, custom pre-trade analytics, risk reports and real-time dashboards.
“Python enables clients to be incredibly productive and it has a rich ecosystem that is ideally suited to portfolio and risk analysis,” said James Church, VP of R&D at FINCAD. “The F3 Python toolkit goes far beyond a simple Python API, and brings together best-of-breed pricing and risk analytics, enterprise scalability, data management and UI tools so that teams can collaborate on ideas, then take them quickly and easily into production.”
The FINCAD F3 Python toolkit includes an F3 Python SDK, F3 Python MicroServices and F3 Python Trade Scripting which enable users to:
- Rapidly deliver custom analytics: Leverage Numpy, Scipy, pandas, Plotly and other standard Python libraries with the most up-to-date Python features to create custom analytics, such as portfolio optimizers, which can be integrated into other applications.
- Easily create custom applications and reports: Native integration with Jupyter Notebooks and Jupyter Lab, PyCharm, Visual Studio and Visual Studio Code, enable faster report and application development with familiar tools, without needing to learn a new development environment. Also included are tools for building rich, interactive UIs without being a developer; and it comes with a complete set of widgets for reporting, selecting books, trades and models, and for handling many types of financial inputs and outputs.
- Quickly model and script complex payoffs: Use Python’s concise, highly expressive syntax with F3 analytics and data. Complex modeling and scripting can be abstracted away or dealt with using data-driven approaches.
“With enterprise portfolio and risk systems, one size doesn’t fit all,” noted Bob Park, FINCAD President and CEO. “Every investment firm is unique, and their software should be flexible and able to adapt to their specific needs, workflows and requirements. With FINCAD F3, firms don’t have to settle for software that is ‘good enough’, nor do they have to make compromises. They get the unparalleled combination of powerful out-of-the-box functionality and the flexibility for unlimited customization using versatile tools such as Python.”
About FINCAD
FINCAD is the leading provider of valuation and risk solutions for derivative and fixed income portfolios. An industry standard since 1990, our advanced analytics, flexible architecture and patented technology enable better investment and risk management decisions. We are committed to helping our clients solve their toughest challenges, without compromise. Clients include leading global asset managers, hedge funds, insurance companies, pension funds, banks and auditors. For more information, visit www.fincad.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005479/en/
Contact information
Media
Rob Garfield
r.garfield@fincad.com
+1
646 217 4572
or
Follow Us
LinkedIn
Twitter
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release
IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead
HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release
HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H
Norwegian Tech Firm Builds Military Command Center in 24 Hours6.6.2025 14:45:00 EEST | Press release
The solution was showcased during a military exercise led by the Dutch Ministry of Defence and has already sparked interest from NATO members and civil protection agencies across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606640770/en/ Cyviz demonstrates rapid deployment capability with a mobile, container-based control room for defense and crisis response Cyviz and its partners constructed the command room inside a 14-ton container designed for transport on standard military vehicles and resistant to machine gun fire. The unit was deployed at a military base in the Netherlands, where Cyviz was tasked with delivering a fully functional command-and-control environment, under strict time constraints and in a high-stakes simulation. "You don’t have time to build control rooms from scratch during an emergency. That’s why we designed something that’s mobile, fast to deploy, and fully secure”, says John van Laerhove
Multiply Group Lights up the World With the Launch of Multiply Media Group, Creating a Media Powerhouse Headquartered in the UAE6.6.2025 13:52:00 EEST | Press release
Multiply Group (ADX: MULTIPLY), the Abu Dhabi-based investment holding company, today launches Multiply Media Group (MMG), uniting the three market-leading out-of-home (OOH) companies under its portfolio to create a new media powerhouse headquartered in the UAE. The combination of BackLite Media, Viola Media and Media 247 under Multiply Media Group represents a significant move that will shape the future of tech-enabled media in the UAE and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606708480/en/ Multiply Group lights up the world with the launch of Multiply Media Group, creating a media powerhouse headquartered in the UAE (Photo: AETOSWire) Samia Bouazza, GCEO and Managing Director of Multiply Group, said: “The launch of Multiply Media Group represents the most significant media consolidations in the UAE. By bringing together market-leading media assets under a single AI & tech-driven group, we are reinforcin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom